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ABSTRACT: The major pathological hallmarks of Alzheimer’s disease (AD) are the
progressive aggregation and accumulation of beta-amyloid (Aβ) and hyperphosphorylated tau
protein into neurotoxic deposits. Aβ aggregation has been suggested as the critical early inducer,
driving the disease progression. However, the factors that promote neurotoxic Aβ aggregation
remain elusive. Imaging mass spectrometry (IMS) is a powerful technique to comprehensively
elucidate the spatial distribution patterns of lipids, peptides, and proteins in biological tissue
sections. In the present study, matrix-assisted laser desorption/ionization (MALDI) mass
spectrometry (MS)-based imaging was used on transgenic Alzheimer’s disease mouse
(tgArcSwe) brain tissue to investigate the sphingolipid microenvironment of individual Aβ
plaques and elucidate plaque-associated sphingolipid alterations. Multivariate data analysis was
used to interrogate the IMS data for identifying pathologically relevant, anatomical features
based on their lipid chemical proﬁle. This approach revealed sphingolipid species that distinctly
located to cortical and hippocampal deposits, whose Aβ identity was further veriﬁed using
ﬂuorescent amyloid staining and immunohistochemistry. Subsequent multivariate statistical
analysis of the spectral data revealed signiﬁcant localization of gangliosides and ceramides species to Aβ positive plaques, which
was accompanied by distinct local reduction of sulfatides. These plaque-associated changes in sphingolipid levels implicate a
functional role of sphingolipid metabolism in Aβ plaque pathology and AD pathogenesis. Taken together, the presented data
highlight the potential of imaging mass spectrometry as a powerful approach for probing Aβ plaque-associated lipid changes
underlying AD pathology.
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■ INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent neuro-
degenerative disorder. The neuropathology of AD is charac-
terized by the formation of protein deposits in the brain
including intercellular neuroﬁbrillary tangles consisting of
hyperphosphorylated tau protein1 and extracellular plaques
formed by aggregated amyloid-β (Aβ) peptides.2,3 Aβ peptides
rapidly aggregate to oligomers, protoﬁbrils and ﬁbrils,
eventually leading to formation of extracellular plaques. Little
is known about the molecular mechanisms of how monomeric
Aβ peptides are converted to neurotoxic, aggregated forms that
are rich in β-sheet motifs. A number of biochemical and clinical
studies suggest that in addition to peptide centric mechanisms,
changes in neuronal lipid metabolism may be implicated in AD
pathogenesis and plaque pathology in particular.4,5 Further-
more, genetic predisposition with the apolipoprotein E (APOE)
ε4 allele, a lipid transporter protein, was identiﬁed as the major
risk factor to develop sporadic AD, further suggesting a possible
role for lipids in AD pathogenesis.6−9 Hence, several studies on
the relevance of neuronal lipid species associated with AD
pathology, including sphingolipids,10,11 cholesterol,12 and
phospholipids13 have been reported. In particular, a potential
role in AD pathogenesis has been suggested for a number of
sphingolipid species, including ceramides,7,14 sulfatides,14,15 and
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gangliosides.16−19 Therefore, in order to further delineate the
relevance of sphingolipids in AD pathogenesis, it is important
to outline their spatial distribution proﬁle in situ. Genetically
altered mouse models are of central relevance to probe the
molecular mechanisms of AD pathology.20,21 For instance, a
transgenic mouse model of AD, with mice carrying both the
Arctic (E693G) and the Swedish (K670M/N671L) mutations
(tgArcSwe) of amyloid precursor protein (APP) has been
developed. These mice exhibit in extensive Aβ deposition with
an onset at the age of 5−6 months, and are a well-suited model
system to study molecular mechanisms for Aβ deposition.22
In order to characterize disease pathology in situ, advanced
molecular imaging techniques are required including imaging
mass spectrometry (IMS). This technique is often referred as
molecular histology and allows to generate spatial intensity
distribution maps of molecular species in complex biological
tissues.23 In particular, matrix assisted laser desorption/
ionization (MALDI) based IMS is a well suited IMS modality
to probe neuronal lipids,24 including gangliosides25 as well as
for in situ characterization of endogenous neuropeptides26,27
associated with neurodegenerative disease pathology. Indeed,
MALDI-IMS, has been previously successfully demonstrated
for probing Aβ peptide pathology in tgArcSwe mice.28
In the present study, MALDI-IMS was employed to examine
the sphingolipid microenvironment, including ganglioside-,
sulfatide- and ceramide- localizations to cortical and hippo-
campal Aβ plaques in tgArcSwe mice. Here, IMS was used in
conjunction with multivariate statistical analysis tools to identify
regional plaque-associated changes in neuronal sphingolipid
chemistry.
■ RESULTS AND DISCUSSION
MALDI Imaging MS Reveals Distinct Localization of
Neuronal Sphingolipid Species on the Cortical and
Hippocampal Amyloid-β Plaques. In MALDI-IMS, sample
preparation includes deposition of a matrix species, dissolved in
an aqueous/organic solvent system onto the tissue sections.
However, this process can result in lateral analyte diﬀusion and
disturbance of tissue morphology. In contrast, sublimation is a
solvent free approach for matrix deposition that overcomes
analyte delocalization issues arising with wet matrix application
and hence allows for high-spatial resolution.29 Previously,
sublimation of 1,5-diaminonaphthalene (1,5-DAN) for MALDI
IMS was shown to give enhanced signal intensity for neuronal
lipid species at high spatial resolution, particularly in negative
ion mode.30 In the present study, 1,5-DAN sublimation was
therefore used for MALDI-IMS analysis of neuronal
sphingolipids in tgArcSwe mice. The acquired image data
were investigated by using unsupervised multivariate statistics
based on hierarchical clustering analysis (bisecting k-means) in
order to obtain image segmentation of anatomical regions of
interest based on their lipid chemical proﬁle. Here, image
segmentation identiﬁed deposit-like features in the cortex and
hippocampus (Figure 1A,B). These features were assigned as
individual regions of interest (ROI) and correlated to the
processed MS data, in order to identify the associated chemical
species that allowed image segmentation of the regions.
Inspection of the corresponding variables revealed local-
ization of various sphingolipid species to the plaque-like
features, including ceramides and gangliosides. Visualization
of single ion intensity distributions (i.e., single ion images) for
the individual ceramide (e.g., Cer(d18:1/12:0), m/z 480.5,
Figure 1C) and ganglioside species (Figure 4) showed a
consistent deposit-like distribution patterns throughout the
cortical and hippocampal regions. Hence, the here employed
workﬂow for unbiased segmentation of the complex imaging
data was found to be a strong approach for elucidating the
chemical composition of the plaque-like deposits.
Amyloid-β Plaque Identiﬁcation and Validation by
Subsequent Fluorescent Histochemical Amyloid Stain-
ing. In order to verify the potential plaque identity as observed
for individual ceramide- and ganglioside-accumulations, includ-
Figure 1. Multivariate image analysis of MALDI-IMS data reveals cortical and hippocampal sphingolipid accumulations in tgArcSwe mouse brain.
(A) Bright ﬁeld image showing dorsolateral part of a coronal section used for IMS analysis. Anatomical regions are annotated as follows: Ctx, cortex;
WM, white matter; LV, lateral ventricle; hipp, hippocampus; DG, dentate gyrus of the hippocampus. (B) Segmentation map obtained from
multivariate image analysis of the MALDI-IMS data. Bisecting k-means based hierarchical clustering analysis identiﬁed plaque-like features (green,
yellow, orange) in the cortex and hippocampus based on the encoded chemical information. Inspection of the associated variables (m/z values)
expressing the clustering behavior, revealed m/z values localizing to anatomical features. (C) This includes, e.g., Cer(d18:1/12:0) at m/z 480.5 as
further veriﬁed by the corresponding single ion image as a representative plaque associate sphingolipid species. Scale bar = 0.5 mm.
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ing e.g. Cer(d18:1/12:0) (Figure 2A, B), histochemical staining
was performed using a luminescent conjugated oligothiophene
(LCO), h-FTAA, a ﬂuorescent amyloid probe (Figure 2C).31
Here, a strong colocalization was observed for amyloid staining
and distributions proﬁles of distinct sphingolipid species as
identiﬁed by MALDI-IMS (Figure 2D). Furthermore, in order
to conﬁrm the speciﬁcity of the chemical amyloid staining to
Aβ ﬁbrils, double staining of h-FTAA and Aβ immunohis-
tochemistry (IHC) was performed using a monoclonal Aβ
antibody (Aβ1−16, 6E10). The ﬂuorescent imaging results
show clear double positive staining of the plaques for both h-
FTAA and Aβ, thereby conﬁrming the Aβ identity of the h-
FTAA stained deposits (Supporting Information Figure S-1A−
C).
In addition, to further verify the lipid localizations to amyloid
plaques, a bottom up multivariate, correlation analysis approach
was used. Here, both imaging MS data and ﬂuorescent staining
data (h-FTAA and IHC) were coregistered in the SciLs
software (Figure S-1D,E). This was followed by annotation of
h-FTAA/Aβ double positive features in the ﬂuorescence
imaging data and correlation analysis to the whole imaging
data set. The results revealed the most prominent variables (m/
z values) that correlate with Aβ and h-FTAA double positive
plaque regions (Figure S-1D,E). Here, the most signiﬁcant
peaks above a certain threshold at p < 0.05 signiﬁcance level
could indeed be attributed to sphingolipid species, including m/
z peaks corresponding to gangliosides GM2, GM3 as well as
ceramide species Cer(d18:1/12:0), Cer(d18:1/14:0) and
Cer(d18:1/18:0) and sulfatides, thereby further supporting
the multivariate image analysis results (Figure S-1D,E).
Plaque-Associated Alterations of Sphingolipids. Neu-
ronal membrane-derived sphingolipids play important roles in
biological processes. This includes signal transduction, cell
recognition and senescence, either through regulating the roles
of membrane-associated receptors or by acting as a precursor of
bioactive lipid mediators. Recently, it has been reported that
deregulated sphingolipid metabolism could play a role in AD-
associated amyloid processing, Aβ ﬁbrillogenesis and impair-
ment of synaptic function.11,32 It has been widely reported that
Aβ interacts with gangliosides17,33 with high aﬃnities,34 thereby
adopting an altered structural conformation through its binding
to GM1 and potentially other ganglioside species.16 This results
in ganglioside-Aβ peptide adduct formation, which in turn was
found to trigger Aβ ﬁbrillogenesis in AD brain.35,36 Moreover,
increased membrane-associated oxidative stress and excessive
production and accumulation of ceramides are observed along
with sulfatide reduction in association with AD.37,38 In order to
investigate the sphingolipid content for individual Aβ plaques
in diﬀerent brain regions as previously outlined by image
analysis, MALDI-IMS spectral data of individual ROI,
comprising Aβ deposits and corresponding adjacent control
areas, were annotated and evaluated by statistical analysis. Here,
IMS data from amyloid-positive deposit regions and adjacent
control regions within either the cortex or the hippocampus
were extracted from the data of three diﬀerent animals (n = 3)
and submitted for two class, paired t-statistics. Nonplaque
control regions, representing aggregate-free areas were assigned
Figure 2. Identiﬁcation of Aβ deposits localized with MALDI-IMS using ﬂuorescent amyloid staining. (A) Single ion image of m/z 480.5
(Cer(d18:1/12:0)) using MALDI-IMS with 10 μm spatial resolution. (B) Magniﬁed single ion images of m/z 480.5 from the cortex. (C)
Histologically identiﬁed plaque, stained with h-FTAA reveals Aβ ﬁbril structures in the cortical regions (D) colocalized with the accumulation
observed in the magniﬁed single ion images of m/z 480.5. Scale bars for (A) = 400 μm and (B−D) = 100 μm.
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based on the ﬂuorescent amyloid staining. Statistical analysis
was performed using the SAM (statistical analysis of micro-
arrays) approach for unbiased interrogation of the imaging data
sets.
In SAM, a score is calculated for each variable (m/z value)
that measures the strength of the relationship between peak
intensity and the sample group (i.e., response variable; plaque
vs control). Here, repeated permutations of the data were used
in order to determine if the intensity of each variable was
signiﬁcantly diﬀerent for the two sample groups. The results are
presented in plots where the calculated (observed) score is
displayed for each variable (m/z value) as a function of the
“expected” score, which is calculated from the ﬂuctuations in
the data, assuming that there is no diﬀerence between the
groups. An observed score that is signiﬁcantly larger than the
expected score thus indicates a signiﬁcant diﬀerence between
the groups for this variable. The results show a signiﬁcant (p <
0.05) increase (Figure 3, red) or decrease (Figure 3, green) of
various m/z signals in all plaque ROIs compared to the control
areas. A majority of the signiﬁcantly diﬀerent peaks could be
assigned to sphingolipid species. This included gangliosides and
ceramides that were increased in hippocampal and cortical
amyloid deposits (Figures 4A−H and S-2). In contrast,
sulfatide species displayed an inverse localization pattern and
were decreased in plaque ROI in both cortex and hippocampus
(Figures 5A−D and S-2). The distinct localization of ceramides
and gangliosides to the plaque regions was prominent when
inspecting the ROI spectral data (Figure S-3a−c). Here,
characteristically higher peak intensities are observed for m/z
peaks corresponding to, e.g, Cer(d18:1/18:0), GM2(d18:1/
18:0), and GM3(d18:1/18:0) (Figure S-3d). Moreover, to
further demonstrate that the diﬀerent peak levels are related to
amyloid plaque pathology, MALDI IMS data from 18 month
old control animals were acquired (Figures S-3a and S-4). Here,
as expected no plaque pathology was observed. Furthermore,
no plaque-like accumulation pattern were observed for the
respective sphingolipid species or any other lipid peaks (Figure
S-4). In addition to the general statistics of the ROI spectral
data, the technical variation of the here employed sample
preparation and acquisition was estimated. For that three
sections from one animal were collected and prepared and
analyzed at three diﬀerent occasions. Following ROI
annotation, spectra extraction, and processing, the average
relative standard deviation of the three technical replicates was
calculated and found to be 20.75%.
In order to verify the lipid identities and draw biologically
relevant conclusions, further means of molecular identiﬁcation
beyond accurate mass assignments are imperative. Therefore,
MS/MS experiments were performed directly in situ on the
tissue sections following DAN sublimation. Here, the majority
of the signiﬁcantly changed sphingolipid species were
successfully identiﬁed based on their fragment ions (Figure S-
5).39,40
Based on the accurate mass and MS/MS data, the various m/
z signals could be attributed to several ceramides, including m/z
564.6, Cer(d18:1/18:0), m/z 508.5, Cer(d18:1/14:0) and m/z
480.5, Cer(d18:1/12:0) (Figure S-5a−c) as well as ganglioside
species such as m/z 1544.9, GM1(d18:1/18:0), m/z 1382.8,
GM2(d18:1/18:0) and m/z 1179.7, GM3(d18:1/18:0) (Figure
S-5d−f).
Inspection of single ion images generated for the various
sphingolipid species revealed that both gangliosides and
ceramides were enriched in Aβ deposits in the hippocampus
and somatosensory cortex (Figure 4A-H). In contrast, some
cortical sulfatides (ST) detected with MALDI-IMS and
validated by in situ MS/MS, including ST(18:0) ((3′-
sulfo)Galβ-Cer(d18:1/18:0)) and ST(24:1) ((3′-sulfo)Galβ-
Cer(d18:1/24:1)) (Figure S-5g,h), were signiﬁcantly decreased
in the plaques as compared to the adjacent gray matter control
area (Figure 5A−D).
Previous studies reported that gangliosides GM2, GM3
increased in multiple brain regions including frontal and
temporal cortex whereas GM1 was decreased in AD compared
with matched controls.11,41,42 In the present study, no
substantial changes in plaque-associated GM1 levels were
observed in either of the brain regions. This is deviating from
previous observations, where a reduction in gangliosides was
found in gray matter regions in AD patients43 together with a
corresponding increase in CSF levels of GM1.18 This can be
explained twofold. First, previous studies relied solely on
antibody based methods for characterizing ganglioside
expression in situ. Mass spectrometry is superior with respect
to molecular speciﬁcity and allows thereby accurate annotation
Figure 3. Statistical analysis of peak intensity diﬀerences between
plaques and adjacent control areas. Two class, paired analysis was
performed using the SAM technique in the somatosensory cortex (A)
and hippocampus (B). The graphs depict for each variable (peak m/z
value) the observed SAM score, indicating the relative diﬀerence
between control and plaque. The expected score indicates the random
ﬂuctuation when there is no diﬀerence between the two groups. Red
marked variables indicate m/z values that are increased in the plaque
compared to the control, where the diﬀerence of the observed (SAM)
versus the expected score is above a certain threshold (indicated by
thin lines), representing the 95% signiﬁcance level. Green variables
indicate m/z peaks that are lower in the plaque region as compared to
the immediate local proximity.
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and characterization of local changes of distinct ganglioside
isoforms. Second, the here reported localizations were spatially
resolved and attributed to plaque features at 10−30 μm spatial
resolution. Previous ﬁndings were performed on tissue extracts
where spatially conﬁned changes are convoluted.
Interestingly, an accumulation of ceramides was observed in
the vicinity of the plaque regions where sulfatides were
decreased (Figure 5E, F). Ceramide increase and sulfatide
reduction14,38 can be explained by accelerated lysosomal
degradation of neuronal gangliosides (GM1, GD1, and GT1)
and sulfatides in the plaque regions, as observed during cell
death in AD pathology.42,44 This can furthermore trigger an
excessive accumulation of ceramides and ganglioside (GM2,
GM3) species around cortical and hippocampal Aβ plaques
either as a consequence of altered ganglioside catabolism or
inhibited lysosomal storage and degradation of GM2 and
Figure 4. Cortical and hippocampal plaque-associated accumulation of gangliosides and ceramides in tgArcSwe brain. Statistical analysis (SAM) of
ROI spectral data revealed plaque-associated increase of gangliosides and ceramide species in the cortex (Ctx) and hippocampus (Hipp). Individual
plaque ROIs were compared with adjacent control regions within the same tissue section and brain region. (A−D) Single ion images demonstrated
that GM1(d18:1/16:0), [M − H]− 1544.9 (A) was prominent in both brain regions but did not localize to plaques. In contrast, GM2(d18:1/18:0),
[M − H]− 1382.8 (B), GM3(d18:1/18:0), [M − H]− 1179.7 (C), and GM3(d18:1/20:0), [M − H]− 1207.8 (D) were found to be signiﬁcantly (*p
< 0.05) increased in both cortical and hippocampal plaques. (E−H) Several ceramides, including Cer(d18:1/12:0), [M − H]− 480.5 (E);
Cer(d18:1/14:0), [M − H]− 508.5 (F); Cer (d18:1/18:0), [M − H]− 564.6 (G), and Cer(d18:1/24:1), [M − H]− 646.8 (H) were found to be
signiﬁcantly (*p < 0.05) elevated in the plaques as compared to the control areas in both regions (mean ± SD). Scale bars for (A)−(H) = 0.5 mm.
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GM3.44 Similarly, an accumulation of cortical GM2 and GM3
levels and characteristic distribution to extracellular deposits
was recently reported in a genetic mouse model of Hunter’s
disease, a lysosomal storage disorder.45 These and our ﬁndings
suggest that impaired ganglioside hydrolases and lysosomal
degradation might be associated with AD plaque pathology.
This is presumably as a consequence of amyloid aggregation
induced neuronal dysfunction that leads to pathological
characteristics of lysosomal storage disease, and gangliosidosis,
respectively. Taken together, the data suggest a signiﬁcant role
of altered Aβ plaque-associated sphingolipid metabolism in
transgenic AD mice (tgArcSwe).
■ CONCLUSION
The present study demonstrates the potential of MALDI-IMS
for in situ interrogation of the sphingolipid content in
individual Aβ plaques. The results revealed signiﬁcant plaque-
associated accumulation of distinct ceramide and ganglioside
species along with sulfatide depletion, suggesting a prominent
role of sphingolipid metabolism in AD pathology. These data
highlight the potential of this technique for in situ probing of
plaque-associated lipid chemical changes in neurodegenerative
diseases. Further studies are warranted to examine how this
translates to patients with AD.
■ METHODS
Chemicals and Reagents. All chemicals for matrix and solvent
preparation were pro-analysis grade and obtained from Sigma-Aldrich
(St. Louis, MO), unless otherwise speciﬁed. TissueTek optimal cutting
temperature (OCT) compound was purchased from Sakura Finetek
(AJ Alphen aan den Rijn, The Netherlands). The ddH2O was obtained
from a Milli-Q puriﬁcation system (Millipore Corporation, Merck
Millipore, Billerica, MA).
Animals. Transgenic mice (n = 3; 2 male, 1 female), 18 months of
age, with the Arctic (E693G) and Swedish (K670N, M671L)
mutations (tgArcSwe) of human APP were reared ad libitum at the
animal facility at Uppsala University under a 12 h/12 h light cycle.22
The animals were anesthetized with isoﬂurane and sacriﬁced by
decapitation. The brains were dissected quickly with 3 min
postmortem delay and frozen on dry ice. All animal procedures
were approved by an ethical committee and performed in compliance
with national and local animal care and use guidelines (DNr #C17/14
at Uppsala University). Frozen tissue sections (12 μm thick; n = 3/
animal) were cut in a cryostat microtome (Leica CM 1520, Leica
Biosystems, Nussloch, Germany) at −18 °C, and collected on special-
coated, conducting glass slides (indium tin-oxide (ITO), Bruker
Daltonics, Bremen, Germany) and stored at −80 °C.
MALDI Matrix Application. Matrix deposition was carried out
using a vacuum sublimation apparatus (Sigma-Aldrich) comprising an
inner ﬂat top and an outer bottom attached to each other by an O-
ring-sealed ﬂange. The chamber was connected to a rough pump
attached to a digital vacuum gauge controller and placed in a heated
sand bath (SiO2, 50−70 mesh particle size, Sigma-Aldrich) on a hot
plate (C-MAG HP 4, IKA Werke GmbH & Co. KG, Staufen,
Germany). Sublimation was performed by the following steps. First,
ITO- glass slides with the thaw mounted mouse brain tissues were
attached to the ﬂat top of the chamber using double-sided conductive
copper tape. Then, 300 mg of 1,5-DAN matrix powder was spread
evenly on the outer bottom of the sublimation chamber, which was
then attached to the top using the O-ring seal. A vacuum of 0.8 mbar
was provided by a membrane pump and the cooler was ﬁlled with ice
(≥0 °C) for condensation of the matrix on the sample slides.
Sublimation was performed monitoring temperature, time of
Figure 5. Plaque associated reduction of sulfatides. Statistical analysis ROI spectral data revealed decreased sulfatide signals in plaque regions within
the cortex (Ctx) and hippocampus (Hipp). (A-B) Sulfatide species, including ST(18:0) (3′-sulfo)Galβ-Cer(d18:1/18:0), m/z 806.6 (A, C); and
ST(24:1) ((3′-sulfo)Galβ-Cer(d18:1/24:1)), m/z 888.6 (B, D), were found to be signiﬁcantly decreased in the deposits as compared to the control
areas in both Ctx and Hipp (p < 0.05; mean ± SD) as veriﬁed by the single ion images (E, F). An overlay of single ion images of ST(18:0), m/z
806.6 (green), with the corresponding ceramide residue (Cer(d18:1/18:0), m/z 564.6 (red)), highlights complementary localization of both species.
(F) Magniﬁcation of marked inset (E) in the lateral Ctx. Scale bars for (A), (B), and (E) = 0.5 mm, F = 0.2 mm.
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application, and deposited amount of matrix. Here, the amount of
deposited matrix onto the tissue sections was optimized varying
between 50 μg/cm2 and 300 μg/cm2. Low amounts yielded too few
lipid signals, whereas high amounts yielded too much matrix derived
signals. The optimized amount of deposited 1,5-DAN matrix was 120
μg/cm2, which is in a good agreement with previous optimization
results.30 and was provided by the following sublimation conditions:
20 min at 130 °C under a stable vacuum pressure of 0.8 mbar.
MALDI Mass Spectrometry. MALDI imaging data were acquired
in duplicates from three biological replicates (n = 3). Imaging MS
analysis of tissue sections were performed on a MALDI TOF/TOF
UltraﬂeXtreme mass spectrometer equipped with SmartBeam II
Nd:YAG/355 nm laser operating at 1 kHz (Bruker Daltonics).
Proﬁling and imaging data acquisitions were performed in reﬂector
negative ion mode under optimized delayed extraction conditions in a
mass range of 300−3000 Da with a source accelerating voltage of −20
kV. A number of 20 laser shots per pixel were acquired to avoid matrix
cluster formation (Figure S-6) and allow for fast data acquisition to
avoid matrix sublimation in the ion source. The spatial resolution was
30 μm for all biological and technical replicates and 10 μm for the
colocalization validation experiments. The laser focus was set to small
for the 30 μm experiments and to minimum for the 10 μm acquisition.
The mass resolution and accuracy in the lipid mass range (at ca. 800
Da) was of M/ΔM 20 000, i.e., 50 ppm. External calibration was
carried out using peptide calibration standard I (Bruker Daltonics).
Image data were reconstructed, root-mean-square (RMS) normalized,
and visualized using the Flex Imaging v3.0 software (Bruker
Daltonics).
Lipid identiﬁcation was performed by comparing accurate mass
measurements with LIPID MAPS database (www.lipidmaps.org). For
conﬁrmation of chemical structures of the selected lipids accumulated
on Aβ plaques, MALDI-LIFT (MS/MS) was performed directly on
the plaque deposits in LIFT negative mode. Here, the precursor ion
selector was set to 0.4% of the precursor m/z for acquisition of parent
ions in PARENT mode (600 shots) followed by one point calibration.
In FRAGMENT mode, the laser energy was increased by 30% on the
attenuator (global oﬀset 20%, range 20%) for post source decay and
TOF/TOF characterization (LIFT) of product ions. Post LIFT
mother ion suppression (PLMS) was enabled. Fragment spectra were
collected until a satisfactory number of productions was observed.
Lipid identiﬁcation was performed based on comparison with
diagnostic fragment ions as previously reported39,40 or curated in
LIPID MAPS.
Data Processing. Prior to analysis all spectra were calibrated
externally using the batch-processing function in Flex Analysis (v 3.0,
Bruker Daltonics). Calibration spectra were obtained from calibrant
solution spots (Protein Calibration Mix 1, Bruker Daltonics) that were
placed adjacent to the tissue slides. Image segmentation of the IMS
data was evaluated in SciLS (v2014, SciLS GmbH, Bremen, Germany).
Regions of interest (ROI) were identiﬁed by bisecting k-mean
clustering based image segmentation. The ROIs were correlated to
mass to charge (m/z) values using the corresponding function
implemented in the software. Average spectra of the annotated ROIs,
as well as control ROIs of similar size adjacent to the plaques, were
exported as csv ﬁles in FlexImaging. Data were reduced through
binning. All ROI data were imported into Origin (v. 8.1 OriginLab,
Northhampton, MA) and peaks and peak widths were detected on
average spectra of each ROI using the implemented peak analyzer
function. The determined bin borders for peak integration were
exported as tab delimited text ﬁle. The bin borders were used for area
under curve (AUC) peak integration within each bin (peak-bin) of all
individual ROI average spectra using an in-house developed R script.
Statistical Analysis. Peak area values for all ROI were evaluated
using the “Statistical Analysis of Microarray data” (SAM, v.3.0) in
Excel (v.2010). The SAM tool, originally developed for microarray
analysis, allows comprehensive and unbiased analysis of signiﬁcant
diﬀerences in abundance levels between two groups. Two classes,
paired analysis of data from plaque ROIs and adjacent control areas
was performed for the diﬀerent anatomical regions, including
hippocampus (Hipp) and cortex (Ctx). Further assessment of
signiﬁcant diﬀerences in individual lipid signals between the groups
was performed with two-tailed, paired t test (95% signiﬁcance level).
Fluorescent Amyloid Staining and Immunohistochemistry.
After MALDI analysis, sections were rinsed in absolute EtOH for 120
s, ﬁxed in 95%EtOH/5%AcOH at −20 °C for 8 min, 70%EtOH at
−20 °C for 30 s, 70%EtOH at RT for 30 s, and stored in PBS prior to
staining. For amyloid staining, 30 min incubation in heptameric formyl
thiophene acetic acid (h-FTAA), diluted to a ﬁnal concentration of 3
mM in PBS, was used. For antibody-based visualization of Aβ, a
monoclonal antibody speciﬁc for the Aβ1−16 epitope (6E10, 1 mg/
mL, BioLegend, San Diego, CA) was used as primary antibody, and
goat antimouse IgG conjugated to Alexa Fluor 647 (Thermo Fisher
Scientiﬁc) was used as secondary antibody.
Tissue was blocked for 1 h at room temperature (RT) in PBS based
blocking solution containing 5% normal goat serum (NGS, Invitrogen,
Thermo Fisher Scientiﬁc, Carlsbad, CA), 2% bovine serum albumin
(BSA, Sigma-Aldrich), and 0.3% Triton-X100 (TX100, Sigma-
Aldrich). Incubation with primary antibody (1:500) was performed
overnight at 4 °C, and with secondary antibody (1:1000) for 1 h at
RT, both diluted in PBS based diluent solution (0,05% NGS, 0.02%
BSA, 0.3% TX100). Unspeciﬁc binding of the secondary antibody was
assessed by incubation of in diluent solution without the primary
antibody. Each incubation step was followed by 3 × 5 min rinse in
PBS. Prior to imaging tissue was mounted with Prolong Gold antifade
reagent (Thermo Fisher Scientiﬁc) and dried for 2 h at RT. Imaging
was performed using a wide ﬁeld microscope (Axio Observer Z1,
Zeiss, Jena, Germany).
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